Section Arrow
ANAB.NASDAQ
- AnaptysBio
Quotes are at least 15-min delayed:2025/12/19 08:50 EST
Pre Market
Last
 47.89
+0.36 (+0.76%)
Bid
47.54
Ask
50.33
High 48.95 
Low 46.31 
Volume 309 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
47.53 
1-M High
-- 
Volume 
-- 
Bid
47.54
Ask
50.33
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
1.32B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.82/-4.68
Enterprise Value
1.33B
Balance Sheet
Book Value Per Share
-1.06
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
91.28M
Operating Revenue Per Share
0.54
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
Pre Market 26.6 +0.2 +0.76%
ZVRAZevra Therapeutics-------- 
Pre Market 8.12 +0.02 +0.25%
ZURAZura Bio Limited-------- 
Pre Market -- -- --
ZNTLZentalis Pharmaceuticals-------- 
Pre Market 1.42 0 0.00%
ZLABZai Lab Limited-------- 
Pre Market 17.54 +0.36 +2.10%
Industry overview quotes are at least 15 minutes delayed
Business Description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) anda Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.